Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 1996 by NIH AIDS Clinical Trials Information Service.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:
NCT00002318
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: January 1996
  Purpose

To determine the efficacy of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the treatment of severe AIDS-related Kaposi's sarcoma (KS) by comparison with the established therapy ABV: Adriamycin (doxorubicin)/bleomycin/vincristine. To evaluate the safety and tolerance of DOX-SL compared to ABV in a population of AIDS patients with severe KS.


Condition Intervention Phase
Sarcoma, Kaposi
HIV Infections
Drug: Doxorubicin hydrochloride (liposomal)
Drug: Bleomycin sulfate
Drug: Vincristine sulfate
Drug: Doxorubicin hydrochloride
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Official Title: Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Adriamycin, Bleomycin, and Vincristine (ABV) in the Treatment of Severe AIDS-Related Kaposi's Sarcoma

Resource links provided by NLM:


Further study details as provided by NIH AIDS Clinical Trials Information Service:

Estimated Enrollment: 225
Detailed Description:

Patients are randomized to receive either DOX-SL or the ABV combination. Infusions are given on day 1 and every 2 weeks for a total of six cycles. Kaposi's sarcoma lesions are evaluated prior to every cycle, at the end of the last treatment cycle, and 4 weeks following the end of the last treatment. Patients must agree to have one or more representative KS lesions biopsied.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

  • Prophylaxis for PCP, cryptococcal, and herpes infections, and antiretroviral therapy (e.g., AZT, ddC, ddI) provided these doses have been stable for at least 1 month.
  • Therapy for tuberculosis, fungal, and herpes infections except with potentially myelotoxic chemotherapy.
  • Foscarnet for new episodes of cytomegalovirus infection.
  • Colony-stimulating factors and erythropoietin.

Patients must have:

  • Biopsy-proven, progressive, AIDS-related Kaposi's sarcoma, with any of the following:
  • At least 25 mucocutaneous lesions.
  • Ten or more new lesions in the prior month.
  • Documented visceral disease with at least two accessible cutaneous lesions.
  • Two accessible cutaneous lesions with edema.
  • Documented anti-HIV antibody.
  • No active opportunistic infection with mycobacteria, cytomegalovirus, toxoplasma, Pneumocystis carinii, or other microorganisms (if under treatment with myelotoxic drugs).
  • Life expectancy > 4 months.

NOTE:

  • Patients who respond to therapy on this protocol, as well as those who fail the ABV combination, are eligible to enter the Liposome Technology open trial using DOX-SL alone.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • Clinically significant cardiac, hepatic, or renal disease.
  • Peripheral neuropathy, signs of moderate to severe sensory loss, or moderate to marked motor loss.
  • Inability to comply with the study.

Concurrent Medication:

Excluded:

  • Other cytotoxic chemotherapy.
  • Ganciclovir.

Patients with the following prior conditions are excluded:

  • Prior neoplasms treated with extensive chemotherapy that, in the investigator's opinion, has led to irreversibly compromised bone marrow function.
  • History of idiosyncratic or allergic reaction to bleomycin or vincristine.

Prior Medication:

Excluded:

  • Prior anthracycline therapy.
  • Cytotoxic chemotherapy or interferon treatment within the past 4 weeks.

Prior Treatment:

Excluded:

  • Radiation or electron beam therapy within the past 3 weeks.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002318

Locations
United States, California
East Bay AIDS Ctr
Berkeley, California, United States, 94705
Pacific Oaks Med Group
Beverly Hills, California, United States, 90211
Hematology - Oncology Med Group of San Fernando Valley
Encino, California, United States, 91436
Dr Becky Miller
Los Angeles, California, United States, 90048
Apogee Med Group
San Diego, California, United States, 92103
UCSF - San Francisco Gen Hosp
San Francisco, California, United States, 94110
Kaiser Permanente Med Ctr
San Francisco, California, United States, 94115
San Francisco Veterans Administration Med Ctr
San Francisco, California, United States, 94121
UCSF
San Francisco, California, United States, 94117
UCSF
San Francisco, California, United States, 941430324
Pacific Oaks Med Group
Sherman Oaks, California, United States, 91403
United States, District of Columbia
Dr Mahmoud Mustafa
Washington, District of Columbia, United States, 20037
United States, Florida
Univ of Miami School of Medicine
Miami, Florida, United States, 33136
H Lee Moffit Cancer Ctr and Research Institute
Tampa, Florida, United States, 33612
United States, Georgia
American Med Research Institute
Atlanta, Georgia, United States, 30329
Infectious Disease Rsch Consortium of GA / SE Clin Resources
Atlanta, Georgia, United States, 30345
United States, Illinois
Rush Presbyterian Med College
Chicago, Illinois, United States, 60612
Illinois Masonic Med Ctr / The Cancer Ctr
Chicago, Illinois, United States, 60657
Northwestern Med Faculty Foundation
Chicago, Illinois, United States, 60611
United States, Michigan
Henry Ford Hosp
Detroit, Michigan, United States, 48202
United States, Missouri
Washington Univ
St Louis, Missouri, United States, 63108
United States, New York
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263
Saint Vincent's Hosp and Med Ctr
New York, New York, United States, 10011
Saint Luke's - Roosevelt Hosp Ctr
New York, New York, United States, 10023
New York Univ Med Ctr
New York, New York, United States, 10016
United States, Pennsylvania
Graduate Hosp / Tuttleman Cancer Ctr
Philadelphia, Pennsylvania, United States, 19146
United States, Texas
Comprehensive Care Ctr
Dallas, Texas, United States, 75235
Baylor College of Medicine
Houston, Texas, United States, 77030
Sponsors and Collaborators
Sequus Pharmaceuticals
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00002318     History of Changes
Other Study ID Numbers: 134A, LTI-30-10
Study First Received: November 2, 1999
Last Updated: June 23, 2005
Health Authority: United States: Food and Drug Administration

Keywords provided by NIH AIDS Clinical Trials Information Service:
Vincristine
Sarcoma, Kaposi
Liposomes
Doxorubicin
Drug Therapy, Combination
Acquired Immunodeficiency Syndrome
Bleomycin
Drug Carriers

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Sarcoma
Sarcoma, Kaposi
DNA Virus Infections
Herpesviridae Infections
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Connective and Soft Tissue
Neoplasms, Vascular Tissue
RNA Virus Infections
Retroviridae Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Bleomycin
Doxorubicin
Liposomal doxorubicin
Vincristine
Antibiotics, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Enzyme Inhibitors
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on November 25, 2014